Recombinant human serum albumin - Mitsubishi Tanabe Pharma

Drug Profile

Recombinant human serum albumin - Mitsubishi Tanabe Pharma

Alternative Names: Albrec; GB-1057; Medway; RU-10; RU-101

Latest Information Update: 18 May 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Mitsubishi Pharma Corporation
  • Developer Mitsubishi Tanabe Pharma Corporation; Sucampo Pharmaceuticals
  • Class Acute-phase proteins; Albumins; Plasma expanders; Recombinant proteins
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Hypoalbuminaemia
  • Phase II Dry eyes
  • Phase I Haematological disorders

Most Recent Events

  • 18 Feb 2016 Phase-I clinical trials in Haematological disorders in Japan (unspecified route)
  • 10 Feb 2016 R-Tech Ueno terminates phase I trial in Dry eyes in Japan (UMIN000019291)
  • 07 Dec 2015 R-Tech Ueno has been acquired and merged into Sucampo Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top